DNase I is considered safe in human applications, as the recombinant human DNase I was commercialized to treat the lung disease of cystic fibrosis (Lauková et al., 2020; Yang and Montgomery, 2018). The gene discussed is DNASE1; the disease is cystic fibrosis.